Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer

The crosstalk between estrogen and HER2 receptors and cell-cycle regulation sustains resistance to endocrine therapy of HER2- and hormone receptor-positive breast cancer. We earlier reported that women with HER2 and ER-positive breast cancer receiving neoadjuvant dual HER2-block and palbociclib in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gianni, Luca, Colleoni, Marco, Bisagni, Giancarlo, Mansutti, Mauro, Zamagni, Claudio, Del Mastro, Lucia, Zambelli, Stefania, Bianchini, Giampaolo, Frassoldati, Antonio, Maffeis, Ilaria, Valagussa, Pinuccia, Viale, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748500/
https://www.ncbi.nlm.nih.gov/pubmed/35013314
http://dx.doi.org/10.1038/s41523-021-00377-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748500/
https://www.ncbi.nlm.nih.gov/pubmed/35013314
http://dx.doi.org/10.1038/s41523-021-00377-8

Ejemplares similares